细胞周期蛋白依赖激酶
细胞周期蛋白依赖激酶2
帕博西利布
药物发现
CDK抑制剂
激酶
药理学
计算生物学
癌症研究
生物
癌症
细胞周期
生物化学
蛋白激酶A
细胞
遗传学
乳腺癌
转移性乳腺癌
作者
Mohamed A. Said,Mohamed A. Abdelrahman,Mohammed A.S. Abourehab,Mohamed Farès,Wagdy M. Eldehna
标识
DOI:10.1080/13543776.2022.2078193
摘要
Introduction The success of the CDK4/6 inhibitor Ibrance™ (Palbociclib) as an anticancer agent inspired and directed more efforts toward the discovery of selective cyclin-dependent kinase (CDKs) inhibitors. CDK2 is a member of the CDKs family that plays an important role in regulating the progression of cells into both S- and M-phases of the cell cycle. Studies suggest that overexpression of CDK2 may be implicated in tumor growth in cancer.Areas covered This review covers the patent literature of CDK2 inhibitors published between 2017 and 2021. We searched the online databases of the European Patent Office, American Chemical Society, and Google patents.Expert opinion Developing selective CDK2 inhibitors is challenging due to the absence of a previously approved selective CDK2 inhibitor. However, ongoing efforts by Incyte Corporation and Pfizer Inc., which are reported herein, may stand out as a new starting point and bring novel information critical for the medicinal chemistry and drug design scientists in the field of CDK2 inhibitors’ development.
科研通智能强力驱动
Strongly Powered by AbleSci AI